HLA-DQ8/DR3.Abo Transgenic Line

Reference #:

2000-065

Inventors/Contributors

Chella S. David, Ph.D.

Description

Mouse class II-deficient HLA-DQB1*0302, DQA1*0301 (DQ8) transgenic mice are susceptible to severe collagen-induced arthritis (CIA), an animal model for rheumatoid arthritis. To examine whether polymorphism at the DRB1 locus can modulate DQ-restricted arthritis, we generated double- transgenic (DR/DQ) mice. DRB1*0301 (DR3) was introduced into CIA susceptible DQ8.Abeta transgenic mice to generate DQ8/ DR3.AbetaO mice. The HLA-DR molecules in these mice were found to be functional on the basis of their positive/negative selection of the Vbeta T cell repertoire. Introduction of the DR3 transgene had no effect. Cytokine analysis showed a Th1 profile which suggests that DRB1 polymorphism can modulate the disease.

Patent Status

	U.S. Patent Number 5,965,787 Issued October 12, 1999